RT @pashtoonkasi
🆕Published today🗞️
@ASCO #ASCODailyNews

“Utility & Debate of #LiquidBiopsies in Surveillance Setting”

The❓of what go do if someone is #ctDNA➕. My 2 cents👇🏾.

💡Adjuvant-Plus or #MRD-plus setting➡️🆕platform for trials.

@OncoAlert @DrawImpacts

Link: https://dailynews.ascopubs.org/do/utility-and-debate-liquid-biopsy-assays-surveillance-setting#.ZAkizbGuXdg.twitter

RT @YaleCancer@twitter.com

.@DrRoyHerbstYale@twitter.com @politikaterina@twitter.com @MJGrantMD@twitter.com provide insight #ASCODailyNews on the Emerging Treatment Options in the Management of Resistance to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer #NSCLC #lcsm @ASCO@twitter.com @SmilowCancer@twitter.com @YaleMed@twitter.com @YNHH@twitter.com https://dailynews.ascopubs.org/do/emerging-treatment-options-management-resistance-tyrosine-kinase-inhibitors-non-small

🐦🔗: https://twitter.com/YaleCancer/status/1603482778082824192